Last updated: 2026-09-16 10:31:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Connect Biopharma Holdings Limited (CNTB) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1,22, with a market capitalisation of $108,63M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1,06 to $3,82. This page covers its latest market performance, valuation, price trends and company information.
$108,63M | |
$1,20 | |
$29,27 | |
$0,51 | |
$1,17 | |
33,90K | |
879,48K | |
-- | |
$3,82 | |
$1,06 | |
-- | |
-- |
Connect Biopharma Holdings Limited (CNTB) is trading at $1,22 in pre-market trading as of 2026-09-16 10:28:00, up 3,85% ($0,05) from the previous close of $1,17
Pre-market trading shows how investors are pricing CNTB before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Connect Biopharma Holdings Limited (CNTB) moved from $1,84 to $1,22, representing a decline of 33,97% ($0,63).
The stock traded between $1,06 and $2,10 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 2,94 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 5,6%
CNTB is currently trading at $1,22, placing it 5,6% of the way from its 52-week low of $1,06 to its 52-week high of $3,82. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 64 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Connect Biopharma Holdings Limited (CNTB) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.